$29.63
Collegium Pharmaceutical
Performance
Dividends
1W
1M
YTD
1Y
3Y
11/36
Growth
Score
6/36
Dividend
Score
Valuation
PE Ratio
21.5
PS Ratio
1.44
RSI
-
3
PEG Ratio
0.03
1
PRG Ratio
1.02
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule
of 40
75.9%
2
Gross Margin
57.69%
1
Current Ratio
1.08
Return on Assets
2.69%
Return on Equity
19.21%
Return on inv. Capital
7.92%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 631.45M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 69.19M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 377.34M
2018
2019
2020
2021
2022
2023
2024
6
Events
COLL
Collegium Pharmaceutical
in 284 days
after market close
Earnings per Share is expected with - and revenue with - .
COLL
Collegium Pharmaceutical
in 214 days
after market close
Earnings per Share is expected with - and revenue with - .
COLL
Collegium Pharmaceutical
in 102 days
after market close
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Drug Manufacturers - Specialty & Generic
IPO Date
07.05.2015
MaketCap
954.30M
Country
US
CEO
Mr. Vikram Karnani
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Updated 25.06.2025